Myriad Genetics ((MYGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myriad Genetics (MYGN) is collaborating on a clinical study titled SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives. The study aims to evaluate the safety of a novel treatment for metastatic cancer in patients with BRCA1, BRCA2, or PALB2 mutations, which could significantly impact treatment options for these genetic conditions.
The intervention being tested is a combination of chemotherapy drugs—Melphalan, BCNU, Vitamin B12b, Vitamin C, and Ethanol—administered intravenously, followed by an infusion of the patient’s own stem cells. This approach seeks to overcome drug resistance in cancer treatment.
This phase 1 study employs a single-group, non-randomized design without masking, focusing on treatment as its primary purpose. It aims to determine the safety and potential efficacy of the treatment in a controlled setting.
The study began on October 30, 2019, with its latest update submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and ensuring transparency in its development.
The ongoing study could influence Myriad Genetics’ stock performance by showcasing its commitment to innovative cancer treatments. Positive results may boost investor confidence, especially in the competitive field of genetic-based cancer therapies.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.